A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation
Matthew S. Davids(Dana-Farber Cancer Institute), Philippe Armand(Harvard University), Rodrigo Maegawa(Eastern Maine Medical Center), Frederick L. Locke(Moffitt Cancer Center), Corey Cutler(Harvard University), Alex F. Herrera(City of Hope), Yi‐Bin Chen(Massachusetts General Hospital), Vincent T. Ho(Dana-Farber Cancer Institute), Augustine Weber(Harvard University), Asad Bashey, Haesook T. Kim(Dana-Farber Cancer Institute), Catherine J. Wu(Dana-Farber Cancer Institute), David Avigan(Beth Israel Deaconess Medical Center), Pavan Bachireddy(Broad Institute), Alexander P. Boardman(Harvard University), Michael Mazzeo(Harvard University), Robert J. Soiffer(Dana-Farber Cancer Institute), Adrienne Anderson(Harvard University), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Caitlin Costello(University of California San Diego), Howard Streicher(National Cancer Institute), Edward D. Ball(Sheba Medical Center), Sarah Nikiforow(Otsuka (Japan)), Alexandra Savell(Dana-Farber Cancer Institute), Jerome Ritz(Dana-Farber Cancer Institute)
Cited by 98
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k